|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    Á¦Å¸½ÅÆÄÇÁīŸÇö󽺸¶  [Indomethacin]  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | »èÁ¦  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        [A04202491]  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
                     \0 ¿ø/1¸Å(2002.09.01)(Ãֽžడ)
                
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      ¾î±ú°á¸²¿¡ µû¸¥ °ßÅë, ¿äÅë, °üÀýÅë, ±ÙÀ°Åë, °ÇÃÊ¿°(¼Õ, ¼Õ¸ñÀÇ ÅëÁõ), »ó¿Ï°ñ»ó°ú¿°(Å״Ͻº ¿¤º¸¿ì), Ÿ¹Ú, ¿°Á 
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Indomethacin]
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      [ÁÖ¼ººÐÄÚµå:174807CPO ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] 
ÇÃ¶ó½ºÆ½ Çʸ§À» ¶¼°í 1ÀÏ 1~2ȸ ȯºÎ¿¡ øºÎ.     
      	    
     | 
   
  
  
  
   
    | ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë | 
    
        
	  [º¸±â]
     | 
   
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      - Áö±Ý±îÁö º»Á¦(Àεµ¸ÞŸ½Å)¿¡ ÀÇÇÑ ¾Ë·¯Áö Áõ»ó(¹ßÁø, ¹ßÀû, °¡·Á¿ò, ¿Ì µî) ±â¿Õ·ÂÀÚ(ÀÌÀü¿¡ ¾àÀ» »ç¿ëÇØ¼ ¾Ë·¯Áö ±â¿Õ·ÂÀÚ´Â ´Ù½Ã °°Àº ¾àÀ» »ç¿ëÇÏ¸é ½ÉÇÑ Áõ»óÀ» ÀÏÀ¸Å³ °¡´É¼ºÀÌ ÀÖ´Ù.)
 - õ½Ä ±â¿Õ·ÂÀÚ(õ½ÄÀÌ ÀÖ´Â »ç¶÷ÀÌ Àεµ¸ÞŸ½Å µîÀÇ Ç׿°ÁõÁ¦¸¦ »ç¿ëÇϸé õ½Ä¹ßÀÛÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù.)
 - ´ÙÀ½ ºÎÀ§¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù
- ´«ÁÖÀ§, Á¡¸· µî
 - ¹ßÁø, °¡·Á¿ò, »óó
 - ¹«Á», ¹é¼± µî ¶Ç´Â ȳóȯºÎ.
    
 
  
  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    - ÀӺΠ¶Ç´Â ÀӺζó »ý°¢µÇ´Â »ç¶÷
 - Áö±Ý±îÁö ¾àÀ̳ª ÈÀåǰ¿¡ ¾Ë·¯Áö Áõ»ó(¹ßÁø, ¹ßÀû, °¡·Á¿ò, ¹é¼± µî) ±â¿Õ·ÂÀÚ
 - ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷.
 
  | 
   
  
  
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    *  »ç¿ë½Ã ÁÖÀÇ »çÇ×
- º»Ç°Àº ÅëÁõÀ̳ª ºÎÁ¾ µîÀÇ ¿øÀÎÀÌ µÇ´Â º´À» Ä¡·áÇÏÁö ¾Ê°í ÅëÁõÀ̳ª ºÎÁ¾ µîÀÇ Áõ»ó¸¸À» Ä¡·áÇÏ´Â Á¦Á¦À̹ǷΠÁõ»óÀÌ ÀÖ´Â °æ¿ì¸¸ »ç¿ë
 - Á¤ÇØÁø ¿ë¹ýÀ» ÁöŲ´Ù
 - º»Á¦´Â 11¼¼¹Ì¸¸ÀÇ ¼Ò¾Æ¿¡°Ô´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù
 - 11¼¼ÀÌ»óÀÇ ¼Ò¾Æ¿¡°Ô »ç¿ëÇÒ °æ¿ì, º¸È£ÀÚÀÇ Áöµµ °¨µ¶ÇÏ¿¡ »ç¿ë
 - ¿¬¼ÓÇØ¼ 2ÁÖÀÌ»ó »ç¿ëÇÏÁö ¾Ê´Â´Ù
 - ¶¡À» È긮°Å³ª ȯºÎ°¡ Á¥¾î ÀÖÀ» ¶§´Â Àß ´Û°í³ª¼ »ç¿ë
 - ÇǺΰ¡ ¾àÇÑ ºÐÀº »ç¿ëÀü¿¡ ¼Ò¸Å¾ÈÃø ÇǺΠ¾àÇÑ °÷¿¡ 1~2cm Á¤µµÀÇ ÀÛÀº Á¶°¢À» ±âÁØÇؼ 12½Ã°£ Àü¿¡ ºÙÀ̰í, ¹ßÁø, ¹ßÀû, °¡·Á¿ò, ¹é¼± µîÀÇ Áõ»óÀÌ ÀϾÁö ¾Ê´Â °ÍÀ» È®ÀÎÇÏ°í ³ª¼ »ç¿ë
  
* »ç¿ë Áß ¶Ç´Â »ç¿ëÈÄÀÇ ÁÖÀÇ »çÇ×
- º»Á¦ÀÇ »ç¿ë¿¡ ÀÇÇØ ¹ßÁø, ¹ßÀû, Á¾, °¡·Á¿ò, µû²ûµû²ûÇÔ, ¿°¨, °ÇÁ¶°¨ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ã
 - ¼öÀϰ£ »ç¿ëÇØµµ Áõ»óÀÇ °³¼±ÀÌ ¾øÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ã
 - Àå±â°£ ¿¬¿ëÇÏÁö ¾Ê´Â´Ù.
 
  | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    - ¼Ò¾ÆÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°ü
 - Á÷»çÀϱ¤À» ÇÇÇÏ°í °¡´ÉÇÑ ÇÑ ½À±â°¡ ÀûÀº °÷ÀÇ ½Ã¿øÇÑ °÷¿¡ º¸°ü
 - ¿À¿ëÀ» ÇÇÇϰí ǰÁúÀ» À¯ÁöÇϱâ À§ÇØ ´Ù¸¥ ¿ë±â¿¡ ¹Ù²ã ³ÖÁö ¾Ê´Â´Ù.
 - ǰÁúÀ¯Áö¸¦ À§ÇØ ¸¶Áö¸· »ç¿ëºÐÀ» ºñ´Ò¿¡ ³Ö¾î °³ÀÔºÎÀÇ ÁöÆÛ¸¦ ´Ý°í º¸°ü
 - »ç¿ë±âÇÑÀ» °æ°úÇÑ Á¦Ç°Àº »ç¿ëÇÏÁö ¾Ê´Â´Ù.
 
  | 
   
  	
  
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Dµî±Þ 
				        
				         (°æ±¸ Åõ¿© ½Ã 48½Ã°£ ÀÌ»ó »ç¿ëµÇ°Å³ª ÀӽŠ34ÁÖÂ÷ ÀÌÈÄ ¶Ç´Â Ãâ»êÀÌ °¡±î¿î ½ÃÁ¡¿¡ »ç¿ëµÉ °æ¿ì Dµî±Þ. -Briggs G, et al. Drugs in Pregnancy and Lactation 7th edit. )
				        
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Indomethacin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Indomethacin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Antiinflammatory effects of Indomethacin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. 
     | 
   
  
   
    | Pharmacology | 
     
       Indomethacin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Indomethacin, a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. 
     | 
   
  
   
    | Metabolism | 
    
       Indomethacin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C19 (CYP2C19)UDP-glucuronosyltransferase 1-9 (UGT1A9) 
     | 
   
  
   
    | Protein Binding | 
    
       Indomethacin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 97% 
     | 
   
  
   
    | Half-life | 
    
       Indomethacin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 4.5 hours 
     | 
   
  
   
    | Absorption | 
    
       Indomethacin¿¡ ´ëÇÑ Absorption Á¤º¸ Bioavailability is approximately 100% following oral administration and 80??0% following rectal administration. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       IndomethacinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ÀÛ¿ë¹ßÇö½Ã°£ : 30ºÐ À̳»
 
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 4-6 ½Ã°£
 
 - Èí¼ö : ½Å¼ÓÇϰÔ, ¸¹Àº ¾çÀÌ Èí¼öµÊ
 
 - ºÐÆ÷ : ºÐÆ÷¿ëÀû : 0.34-1.57 L/kg.  ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ
 
 - ´Ü¹é°áÇÕ : 90%
 
 - ´ë»ç : °£´ë»ç, Àå°£¼øÈ¯
 
 - ¹Ý°¨±â : 4.5 ½Ã°£.  ½Å»ý¾Æ¿¡¼´Â ¿¬ÀåµÊ
 
 - Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 3-4 ½Ã°£ À̳»
 
 - ¼Ò½Ç : Àå°£¼øÈ¯ Å.  ÁÖ·Î glucuronide Æ÷ÇÕü·Î¼ ½Å¹è¼³
   
     | 
   
  
   
    | Biotransformation | 
    
       Indomethacin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. 
     | 
   
  
   
    | Toxicity | 
    
       Indomethacin¿¡ ´ëÇÑ Toxicity Á¤º¸ The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively. 
     | 
   
  
   
    | Drug Interactions | 
    
       Indomethacin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol	Risk of inhibition of renal prostaglandinsAtenolol	Risk of inhibition of renal prostaglandinsBetaxolol	Risk of inhibition of renal prostaglandinsBevantolol	Risk of inhibition of renal prostaglandinsBisoprolol	Risk of inhibition of renal prostaglandinsCarteolol	Risk of inhibition of renal prostaglandinsCarvedilol	Risk of inhibition of renal prostaglandinsMethotrexate	The NSAID increases the effect and toxicity of methotrexateDiflunisal	Diflunisal increases the effect and toxicity of indomethacinEsmolol	Risk of inhibition of renal prostaglandinsLabetalol	Risk of inhibition of renal prostaglandinsMetoprolol	Risk of inhibition of renal prostaglandinsNadolol	Risk of inhibition of renal prostaglandinsLosartan	Indomethacin decreases the effect of losartanLithium	The NSAID increases serum levels of lithiumOxprenolol	Risk of inhibition of renal prostaglandinsPenbutolol	Risk of inhibition of renal prostaglandinsPindolol	Risk of inhibition of renal prostaglandinsPractolol	Risk of inhibition of renal prostaglandinsProbenecid	Probenecid increases the effect/toxicity of indomethacinSotalol	Risk of inhibition of renal prostaglandinsPropranolol	Risk of inhibition of renal prostaglandinsTimolol	Risk of inhibition of renal prostaglandinsWarfarin	The NSAID increases the anticoagulant effectAcenocoumarol	The NSAID increases the anticoagulant effectDicumarol	The NSAID increases the anticoagulant effectAnisindione	The NSAID increases the anticoagulant effectTorasemide	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticBumetanide	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticFurosemide	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticEthacrynic acid	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticCyclosporine	Monitor for nephrotoxicityAlendronate	Increased risk of gastric toxicityTriamterene	Risk of acute renal impairment with this combination 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Indomethacin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food or antacids to reduce irritation. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Indomethacin¿¡ ´ëÇÑ Description Á¤º¸ A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Indomethacin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule	OralPowder, for solution	IntravenousSuppository	Rectal 
     | 
   
  
   
    | Drug Category | 
    
       Indomethacin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-SteroidalAnti-inflammatory AgentsCardiovascular AgentsCyclooxygenase InhibitorsGout SuppressantsNonsteroidal Antiinflammatory Agents (NSAIDs)Tocolytic Agents 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Indomethacin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Indomethacin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O 
     | 
   
  
   
    | InChI Identifier | 
    
       Indomethacin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)/f/h22H 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Indomethacin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid 
     | 
   
  
   
    | Drug-Induced Toxicity Related Proteins | 
    
      INDOMETHACIN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Tumor necrosis factor receptor superfamily member 1A (TNF-R1) Drug:indomethacin Toxicity:gastric damage and granulocyte infiltration.  [¹Ù·Î°¡±â] Replated Protein:Plasma kallikrein  Drug:indomethacin Toxicity:enterocolitis.  [¹Ù·Î°¡±â] Replated Protein:Heat shock 70 kDa protein Drug:indomethacin Toxicity:denatured proteins.  [¹Ù·Î°¡±â] Replated Protein:c-myc oncogene Drug:indomethacin Toxicity:apoptosis by indomethacin.  [¹Ù·Î°¡±â] Replated Protein:Acetylcholinesterase  Drug:indomethacin Toxicity:enhance contractility of the small intestine.  [¹Ù·Î°¡±â] Replated Protein:G1/S-specific cyclin-D1 Drug:indomethacin Toxicity:arrests endothelial cell proliferation.  [¹Ù·Î°¡±â] Replated Protein:Acetylcholinesterase  Drug:indomethacin Toxicity:enhance contractility of the small intestine.  [¹Ù·Î°¡±â] Replated Protein:P-selectin  Drug:indomethacin Toxicity:Indomethacin induced gastropathy.  [¹Ù·Î°¡±â] Replated Protein:B2 bradykinin receptor Drug:indomethacin Toxicity:enterocolitis.  [¹Ù·Î°¡±â] Replated Protein:Nitric oxide synthase, inducible  Drug:indomethacin Toxicity:gastric damage and granulocyte infiltration.  [¹Ù·Î°¡±â] Replated Protein:Intercellular adhesion molecule 1  Drug:indomethacin Toxicity:Indomethacin induced gastropathy.  [¹Ù·Î°¡±â] Replated Protein:Plasma kallikrein  Drug:indomethacin Toxicity:enterocolitis.  [¹Ù·Î°¡±â] Replated Protein:Integrin alpha-M  Drug:indomethacin Toxicity:experimental dystonia.  [¹Ù·Î°¡±â] Replated Protein:Tumor necrosis factor  Drug:indomethacin Toxicity:gastric damage and granulocyte infiltration.  [¹Ù·Î°¡±â] Replated Protein:Cytochrome b5 Drug:indomethacin  Toxicity:selective effect of a p-chlorophenyl moiety.  [¹Ù·Î°¡±â] Replated Protein:NADH-cytochrome b5 reductase Drug:indomethacin  Toxicity:selective effect of a p-chlorophenyl moiety.  [¹Ù·Î°¡±â] Replated Protein:Epoxide hydrolase Drug:indomethacin  Toxicity:selective effect of a p-chlorophenyl moiety.  [¹Ù·Î°¡±â] 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2014-12-01
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  [ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â]       Á¦¸ñ ¾øÀ½ 
 
    
    2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
    
    1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ  º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
          
    
    
    
    2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
 
 
 
   
  |  
             
             | 
         
         
         | 
         |